News Conference News HFSA 2025 Too Few HF Patients on Guideline-Directed Medical Therapy in VA System Yael L. Maxwell October 06, 2025
News Conference News HFSA 2025 CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF Yael L. Maxwell September 29, 2025
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2023 ANTHEM-HFrEF Fails to Show Benefit of Vagal Nerve Stimulation Over GDMT Yael L. Maxwell October 16, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Daily News HFSA 2021 In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity Michael O'Riordan September 15, 2021
News Conference News HFSA 2021 Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF Michael O'Riordan September 14, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Conference News HFSA 2019 Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF L.A. McKeown September 23, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019